This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

- HC Wainwright & Co. analyst Brandon Folkes initiated coverage on **Traws Pharma, Inc**. (NASDAQ: TRAW) with a Buy rating and announced a price target of $8. Traws Pharma shares closed at $2.16 on Tuesday. See how other analysts view this stock.
- Canaccord Genuity analyst John Newman initiated coverage on **Compass Therapeutics, Inc**. (NASDAQ: CMPX) with a Buy rating and announced a price target of $10. Compass Therapeutics shares closed at $5.22 on Tuesday. See how other analysts view this stock.
- CICC analyst Shanshan Shen initiated coverage on **Linde plc** (NASDAQ: LIN) with an Outperform rating and announced a price target of $510. Linde shares closed at $408.79 on Tuesday. See how other analysts view this stock.
- HC Wainwright & Co. analyst Brandon Folkes initiated coverage on **Pelthos Therapeutics Inc.** (AMEX: PTHS) with a Buy rating and announced a price target of $60. Pelthos Therapeutics shares closed at $25.14 on Tuesday. See how other analysts view this stock.
- LifeSci Capital initiated coverage on **Oculis Holding AG** (NASDAQ: OCS) with an Outperform rating and announced a price target of $55. Oculis Holding shares closed at $18.79 on Tuesday. See how other analysts view this stock.

Considering buying LIN stock? Here’s what analysts think:

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>



<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. analyst Brandon Folkes initiated coverage on <strong>Traws Pharma, Inc</strong>. <a href="https://www.benzinga.com/quote/TRAW" target="_blank" class="ticker-link" data-ticker="TRAW" data-exchange="NASDAQ">(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TRAW">TRAW</a>)</a> with a Buy rating and announced a price target of $8. Traws Pharma shares closed at $2.16 on Tuesday. <a href="https://www.benzinga.com/quote/traw/analyst-ratings">See how other analysts view this stock</a>.</li>



<li>Canaccord Genuity analyst John Newman initiated coverage on <strong>Compass Therapeutics, Inc</strong>. <a href="https://www.benzinga.com/quote/CMPX" target="_blank" class="ticker-link" data-ticker="CMPX" data-exchange="NASDAQ">(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CMPX">CMPX</a>)</a> with a Buy rating and announced a price target of $10. Compass Therapeutics shares closed at $5.22 on Tuesday. <a href="https://www.benzinga.com/quote/CMPX/analyst-ratings">See how other analysts view this stock</a>.</li>



<li>CICC analyst Shanshan Shen initiated coverage on <strong>Linde plc</strong> <a href="https://www.benzinga.com/quote/LIN" target="_blank" class="ticker-link" data-ticker="LIN" data-exchange="NASDAQ">(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LIN">LIN</a>)</a> with an Outperform rating and announced a price target of $510. Linde shares closed at $408.79 on Tuesday. <a href="https://www.benzinga.com/quote/LIN/analyst-ratings">See how other analysts view this stock</a>.</li>



<li>HC Wainwright &amp; Co. analyst Brandon Folkes initiated coverage on <strong>Pelthos Therapeutics Inc.</strong> <a href="https://www.benzinga.com/quote/PTHS" target="_blank" class="ticker-link" data-ticker="PTHS" data-exchange="AMEX">(AMEX:<a class="ticker" href="https://www.benzinga.com/quote/PTHS">PTHS</a>)</a> with a Buy rating and announced a price target of $60. Pelthos Therapeutics shares closed at $25.14 on Tuesday. <a href="https://www.benzinga.com/quote/PTHS/analyst-ratings">See how other analysts view this stock</a>.</li>



<li>LifeSci Capital initiated coverage on<strong> Oculis Holding AG</strong> <a href="https://www.benzinga.com/quote/OCS" target="_blank" class="ticker-link" data-ticker="OCS" data-exchange="NASDAQ">(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OCS">OCS</a>)</a> with an Outperform rating and announced a price target of $55. Oculis Holding shares closed at $18.79 on Tuesday. <a href="https://www.benzinga.com/quote/OCS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>



<p>Considering buying LIN stock? Here&#8217;s what analysts think: </p>



<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/LIN/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="613" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/03090008/image-49-1024x613.png" alt="" class="wp-image-1195374" style="width:655px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/03090008/image-49-1024x613.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/03090008/image-49-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/03090008/image-49-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/03090008/image-49.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>



<p><strong>Read This Next: </strong></p>



<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/12/49158632/top-2-health-care-stocks-you-may-want-to-dump-this-month">Top 2 Health Care Stocks You May Want To Dump This Month</a></strong></li>
</ul>



<p>Photo via Shutterstock</p>